Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis

Completed

Conditions studied: Multiple Sclerosis

In brief

This study is designed to determine whether symptom burden differs by time to infusion.

Key facts

Study ID: NCT04855617
Run by: NYU Langone Health
People needed: 122
Starts: 2020-10-26
Expected to finish: 2022-10-01
Last updated by the study team: 2023-06-15

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Age 18-80
Diagnosis of multiple sclerosis (revised 2017 criteria)
EDSS 0-7
Plans to initiate treatment with ocrelizumab within 6 months or has been on an approved regimen of ocrelizumab for >12 months as part of their clinical care
Individual must be able to provide consent, read/write/comprehend English Language

You may not qualify if…

Clinical relapse within 3 months of first on-study infusion
Cognitive impairment limiting the ability to consent or fill out the electronic survey
Currently pregnant, planning to become pregnant during the study period, or currently breastfeeding
Untreated psychiatric illness (such as major depressive disorder, Bipolar disorder, psychotic disorder, schizophrenia)
Active substance abuse disorder
Significant medical comorbidities (such as history of severe traumatic brain injury, stroke, systemic cancer or chronic infection)
Chemotherapy use within 6 months of first study infusion
Prior treatment with alemtuzumab within 12 months of first study infusion
Prior treatment with a B-cell depleting therapy other than ocrelizumab within 12 months of first on-study infusion

Where it is running

Elliot Lewis Center for Multiple Sclerosis Care — Wellesley, Massachusetts, United States
NYU Langone Health Multiple Sclerosis Comprehensive Care Center (NYULH MSCCC) — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.